Newspaper wrap-up: Investigated ingredient in Baxter’s generic heparin drug made in China
MAJOR PAPERS:
- The active ingredient in Baxter worldly Inc’s (NYSE: BAX) generic version of the anticlotting drug heparin, under research for four deaths and hundreds of not good reactions, was made in China, the Wall Street Journal reported.
- Structured investment vehicles that supply short term debt to fund the purchases of municipal bonds and student loans are under increasing pressure, according to the Wall Street Journal’s “Heard on the Street”. Citigroup Incorporated (NYSE: C), JP Morgan Chase & Co (NYSE: JPM) and Merrill Lynch & Co Inc (NYSE: MER) are among the banks that could be affected.
OTHER PAPERS:
- The New York Times reported that Hewlett-Packard Company(NYSE: HPQ) has settled with The New York Times Company (NYSE: NYT) and McGraw Hill Companies Incorporated’s (NYSE: MHP) BusinessWeek journalists related to a spying scandal that stemmed from obtaining telephone records. The involved parties did not reveal the amount of the settlement.
WEB SITES:
- Mike Zafirovski, CEO of Nortel Networks Corporation (NYSE: NT), said the company would examine possible opportunities to be taken by “when they occur.” Mr. Zafirovski did not comment on rumors of a Motorola Inc (NYSE: MOT) merger, Reuters reported.
Original post by Laurie Pasternack
Related Articles
Newspaper wrap-up: American Capital Strategies tied to Baxter’s Heparin generic problems China quality problems may form Baxter (BAX) the next Mattel (MAT) Novartis plans 2,500 more job cuts in reaction to generic drug war Teva sees strong generic growth For safe, holiday shopping here are 500+ toys not made in China
No comments yet. Be the first.
Leave a reply






























